key: cord-0719497-1kzdvedt
authors: Strauss, Ronald A.
title: Subcutaneous terbutaline as an alternative to metered‐dose inhalers for asthma during the COVID‐19 pandemic
date: 2020-07-02
journal: J Am Coll Emerg Physicians Open
DOI: 10.1002/emp2.12131
sha: 8d7b716fd1e793d6a94e467bdb3820fb2c59cedd
doc_id: 719497
cord_uid: 1kzdvedt

nan

In a well-written and informative article, Whittle et al 1 "Respiratory Support for Adult Patients with COVID-19," correctly recommend against using nebulizer therapy for asthmatics and suggests metereddose inhalers.

During the COVID-19 epidemic, asthmatics will continue to have exacerbations, frequently requiring emergency room care in a physician's office, urgent care center, or emergency department of a hospital. It is recommended that asthmatic patients continue to be managed according to asthma guideline recommendations. 2 Nebulizer use is discouraged unless essential during a pandemic because nebulized therapy is more likely to aerosolize SARS-CoV-2 and increase risk of contagion. As such, asthma therapy delivered by a metered-dose inhaler would be more appropriate in the healthcare setting. 3 Nevertheless, some patients are so tight that using a metered-dose inhaler, even with a spacer, might be problematic, particularly if they have uncontrolled coughing, have severe life-threatening asthma, or those who are uncooperative or unable to follow directions required for the metered-dose inhaler, even with a spacer.

A recent article 4 demonstrated that, in a prospective study, 85 asthmatic patients treated with subcutaneous terbutaline significantly improved after already receiving multiple albuterol treatments with either nebulized aerosols or albuterol metered-dose inhalers.

Advantages of terbutaline over epinephrine include: (1) a more pronounced effect with a longer duration of action on forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), 5 and (2) preferred over epinephrine in pregnancy. 6 Terbutaline is inexpensive and readily accessible, even though a previous survey of physicians in the Cleveland area reveal that 98% of physicians rarely or never use subcutaneous terbutaline for an exacerbation of asthma. 7 From a colleague in New York City reading about my work with terbutaline, "This is great! Not only that, but the feasibility of subcutaneous terbutaline as an administration route during a high-volume/war-like situation is underappreciated."

Additionally, the American College of Allergy, Asthma, and Immunology (ACAAI) has reported that some areas around the country are experiencing shortages in albuterol inhalers as a result of an increased demand, because hospitals are using inhalers rather than nebulizers to treat COVID-19 patients. 8 

Respiratory support for adult patients with COVID-19

Global Strategy for Asthma Management and Prevention

Transmission of coronavirus by nebulizer: a serious underappreciated risk

The treatment of asthma exacerbations with subcutaneous terbutaline

Comparison of the cardiopulmonary effects of subcutaneously administered epinephrine and terbutaline in patients with reversable airway obstruction

Clinical review: severe asthma

A New look at an old drug

A message to asthma sufferers about a shortage of albuterol metered-dose inhalers